PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Infectious Diseases, Department of Internal Medicine, Incheon Medical Center, Incheon, Republic of Korea.\', \'Clinical Trials Center, Chungnam National University Hospital, Daejeon, Republic of Korea.\', \'National Institute for Infectious Diseases \'Prof. Dr. Matei Balș,\' Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.\', \'Celltrion Inc, Incheon, Republic of Korea.\', \'Division of Infectious Diseases, Chungnam National University School of Medicine, Daejeon, Republic of Korea. Electronic address: alice@cnuh.co.kr.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0149-2918(21)00308-810.1016/j.clinthera.2021.08.009
?:hasPublicationType
?:journal
  • Clinical therapeutics
is ?:pmid of
?:pmid
?:pmid
  • 34551869
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.151
?:rankingScore_hIndex
  • 120
is ?:relation_isRelatedTo_publication of
?:title
  • Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34551869>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34551869>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all